立体定向放射外科治疗库欣病:一项国际多中心研究结果
这项国际多中心回顾性队列分析纳入278例库欣病患者,评估伽玛刀立体定向放射外科的疗效与安全性。10年高皮质醇血症累积初始控制率为80%,持久控制率为64%,初治患者为68%;复发率为18%,垂体功能减退为25%,颅神经病变为3%。作者认为该治疗耐受良好且常可控制高皮质醇血症,但可发生复发,术后持续高皮质醇血症者应考虑此治疗,不适合手术者可作为主要治疗,长期内分泌随访至关重要。
要点
- 10年高皮质醇血症累积初始控制率为80%,持久控制率为64%。
- 初治患者10年持久控制率为68%,复发率为18%。
- 垂体功能减退发生率为25%,颅神经病变为3%。
核心结论
- SRS治疗库欣病耐受良好且常可控制高皮质醇血症,但可发生复发。
- 作者认为垂体手术后持续高皮质醇血症者应考虑SRS,不适合手术者可作为主要治疗。
- SRS后长期内分泌随访至关重要。
研究设计与样本
- 国际多中心回顾性队列分析,由国际伽玛刀研究基金会10个医学中心参与。
- 纳入278例库欣病患者,内分泌随访时间超过6个月。
- 干预为伽玛刀立体定向放射外科治疗。
- 主要结局为高皮质醇血症控制,定义为游离尿皮质醇正常化。
- 记录影像学反应和放射不良反应。
主要发现
- 278例患者平均随访5.6年(范围0.5至20.5年),其中22例以SRS作为库欣病的主要治疗。
- 平均边缘剂量为23.7 Gy。
- 10年高皮质醇血症累积初始控制率为80%,皮质醇正常化平均时间为14.5个月。
- 初始皮质醇正常化的患者中复发率为18%;10年持久控制率为64%,以SRS作为主要治疗的患者为68%。
- 放射不良反应包括垂体功能减退(25%)和颅神经病变(3%);视觉缺陷与治疗鞍上池内肿瘤相关(P = 0.01),视觉(P < 0.0001)和非视觉颅神经病变(P = 0.02)均与既往垂体放疗相关。
临床怎么用
- 作者认为,垂体手术后持续高皮质醇血症的患者应考虑SRS。
- 作者认为,不适合手术的患者可将SRS作为主要治疗。
- 作者强调SRS后长期内分泌随访至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Cushing disease (CD) due to adrenocorticotropic hormone-secreting pituitary tumors can be a management challenge. OBJECTIVE: To better understand the outcomes of stereotactic radiosurgery (SRS) for CD and define its role in management. DESIGN: International, multicenter, retrospective cohort analysis. SETTING: Ten medical centers participating in the International Gamma Knife Research Foundation. PATIENTS: Patients with CD with >6 months endocrine follow-up. INTERVENTION: SRS using Gamma Knife radiosurgery. MAIN OUTCOME MEASURES: The primary outcome was control of hypercortisolism (defined as normalization of free urinary cortisol). Radiologic response and adverse radiation effects (AREs) were recorded. RESULTS: In total, 278 patients met inclusion criteria, with a mean follow-up of 5.6 years (0.5 to 20.5 years). Twenty-two patients received SRS as a primary treatment of CD. Mean margin dose was 23.7 Gy. Cumulative initial control of hypercortisolism was 80% at 10 years. Mean time to cortisol normalization was 14.5 months. Recurrences occurred in 18% with initial cortisol normalization. Overall, the rate of durable control of hypercortisolism was 64% at 10 years and 68% among patients who received SRS as a primary treatment. AREs included hypopituitarism (25%) and cranial neuropathy (3%). Visual deficits were related to treatment of tumor within the suprasellar cistern (P = 0.01), whereas both visual (P < 0.0001) and nonvisual cranial neuropathy (P = 0.02) were related to prior pituitary irradiation. CONCLUSIONS: SRS for CD is well tolerated and frequently results in control of hypercortisolism. However, recurrences can occur. SRS should be considered for patients with persistent hypercortisolism after pituitary surgery and as a primary treatment in those unfit for surgery. Long-term endocrine follow-up is essential after SRS.
引用
- Mehta GU, Ding D, Patibandla MR, et al. Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study. J Clin Endocrinol Metab. 2017. PMID: 28938462. doi:10.1210/jc.2017-01385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。